First-ever oral pill to treat anaemia approved

In a defining breakthrough for the global fight against thalassaemia, the US Food and Drug Administration (FDA) has approved ...
Seeking Alpha

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...

First-ever oral pill to treat thalassaemia approved

BHUBANESWAR: In a defining breakthrough for the global fight against thalassaemia, the US Food and Drug Administration (FDA) ...